Apama Medical announces claim coverage in China for electrode-based ablation balloon for the treatment of atrial fibrillation


Apama Medical announced receipt of a Chinese notice of allowance for claims covering their low profile electrode assembly that enables the attachment of flexible electrodes to an ablation balloon for energy delivery and monitoring.

According to a press release, the Chinese patent will complement an existing US patent giving Apama broad claim coverage for electrode-based ablation balloons in the US and China for the treatment of atrial fibrillation. Utilising this patented electrode technology enables Apama to design the only ablation catheter that performs a full pulmonary vein ablation and rotor ablation in a single-shot.

“Accurate energy delivery and monitoring are a challenge during ablation procedures since success often depends on a multitude of discrete catheter manipulations,” stated Amr Salahieh, Apama president and chief executive officer. “Our proprietary design offers multipoint, customisable single-shot ablation and eliminates the need for excessive catheter rotations and serial point ablations. This simplifies the current procedure and reduces time, which allows for more patients to be treated.”

(Visited 127 times, 1 visits today)